Research programme: phosphodiesterase IV inhibitors - CrystalGenomicsAlternative Names: PDE 4 inhibitors research programme - CrystalGenomics; Phosphodiesterase IV inhibitors research programme - CrystalGenomics
Latest Information Update: 16 Jul 2016
At a glance
- Originator CrystalGenomics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma